Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | THRB | P10828 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.65 |
| ▸ | MEN1 | O00255 | 4/20 | 0.65 |
| ▸ | POLB | P06746 | 4/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.59 |
| ▸ | USP2 | O75604 | 2/20 | 0.59 |
| ▸ | RECQL | P46063 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | TSHR | P16473 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | FPR1 | P21462 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30957223 | 0.78 | HTT (0.72) | CYP3A4CYP2C9CYP2D6MAPTTHRB | |
| SCHEMBL31157807 | 0.77 | ALDH1A1 (0.71) | CYP3A4CYP2C9CYP2D6MAPTTHRB | |
| SCHEMBL31120333 | 0.76 | ALDH1A1 (0.70) | CYP3A4CYP2C9CYP2D6MAPTTHRB | |
| SCHEMBL4941399 | 0.75 | MAPT (0.64) | CYP3A4CYP2C9CYP2D6MAPTTHRB | |
| SCHEMBL5449752 | 0.75 | MEN1 (0.61) | CYP3A4CYP2C9CYP2D6MAPTTHRB | |
| SCHEMBL4881075 | 0.75 | HSD17B10 (0.65) | CYP3A4CYP2C9CYP2D6MAPTKMT2A | |
| SCHEMBL4878334 | 0.74 | ALDH1A1 (0.67) | CYP3A4CYP2C9CYP2D6KMT2APOLB | |
| SCHEMBL4938012 | 0.73 | MAPT (0.66) | CYP3A4CYP2C9CYP2D6MAPTTHRB | |
| SCHEMBL4882118 | 0.72 | ENPP2 (0.57) | CYP3A4CYP2C9MAPTTHRBKMT2A | |
| SCHEMBL4878792 | 0.71 | ALDH1A1 (0.66) | CYP3A4CYP2C9CYP2D6KMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149673-A1 | INHIBITORS OF STORE OPERATED CALCIUM RELEASE | CALCIMEDICA, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149673-A1 | INHIBITORS OF STORE OPERATED CALCIUM RELEASE | CALCIMEDICA, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8143269-B2 | Inhibitors of store operated calcium release | CALCIMEDICA, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143269-B2 | Inhibitors of store operated calcium release | CALCIMEDICA, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100087415-A1 | INHIBITORS OF STORE OPERATED CALCIUM RELEASE | CALCIMEDICA, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087415-A1 | INHIBITORS OF STORE OPERATED CALCIUM RELEASE | CALCIMEDICA, INC. (US) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149673-A1 | INHIBITORS OF STORE OPERATED CALCIUM RELEASE | ORAI1, SARAF, RYR2 | CYP3A4 4321/4885CYP2C9 4581/4885CYP2D6 4505/4885 |
| US-20100087415-A1 | INHIBITORS OF STORE OPERATED CALCIUM RELEASE | ORAI1, SARAF, RYR2 | CYP3A4 4321/4885CYP2C9 4581/4885CYP2D6 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.